Prostate cancer (PCa) is one of the leading causes of death for men worldwide. Multi-parametric magnetic resonance (mpMR) imaging has emerged as a non-invasive diagnostic tool for detecting and localising prostate tumours by specialised radiologists. These radiological examinations, for example, for differentiating malignant lesions from benign prostatic hyperplasia in transition zones and for defining the boundaries of clinically significant cancer, remain challenging and highly skill-and-experience-dependent. We first investigate experimental results in developing object detection neural networks that are trained to predict the radiological assessment, using these high-variance labels. We further argue that such a computer-assisted diagnosis (CAD) system needs to have the ability to control the false-positive rate (FPR) or false-negative rate (FNR), in order to be usefully deployed in a clinical workflow, informing clinical decisions without further human intervention. This work proposes a novel PCa detection network that incorporates a lesion-level cost-sensitive loss and an additional slice-level loss based on a lesion-to-slice mapping function, to manage the lesion- and slice-level costs, respectively. Our experiments based on 290 clinical patients concludes that 1) The lesion-level FNR was effectively reduced from 0.19 to 0.10 and the lesion-level FPR was reduced from 1.03 to 0.66 by changing the lesion-level cost; 2) The slice-level FNR was reduced from 0.19 to 0.00 by taking into account the slice-level cost; (3) Both lesion-level and slice-level FNRs were reduced with lower FP/FPR by changing the lesion-level or slice-level costs, compared with post-training threshold adjustment using networks without the proposed cost-aware training.
翻译:高偏差标记的多参数磁共振成像作为非侵入性诊断工具,由专门的放射科医生检测和定位前列腺肿瘤。这些放射检查,例如,将恶性损伤与过渡地区的良性先发性高病分辨,以及确定临床重大癌症的界限,仍然是具有挑战性和高度技能和经验依赖性。我们首先调查开发物体探测神经网络的实验结果,这些网络经过培训,利用这些高逆差标签来预测辐射评估。我们进一步认为,这种计算机辅助诊断系统需要有能力控制假阳性率(FPR)或假阴性率(FNR),以便在临床工作流程中有效部署,为临床决策提供信息,而无需人类进一步干预。这项工作提议建立一个新型的PCA检测网络,纳入对损耗程度敏感的损失,以及根据0至偏差测值测算而增加的切分位值。我们从零比值水平开始的0.19级的临床成本水平调整,从基数到基数水平的FRLF1,分别通过不断降低成本水平。